AZN.L - AstraZeneca PLC

LSE - LSE Delayed Price. Currency in GBp
4,754.50
+15.00 (+0.32%)
As of 12:49PM GMT. Market open.
Stock chart is not supported by your current browser
Previous Close4,739.50
Open4,800.00
Bid4,730.00 x 6100
Ask4,900.00 x 13000
Day's Range4,741.50 - 4,820.50
52 Week Range4,260.00 - 5,520.00
Volume564,637
Avg. Volume2,342,381
Market Cap60.211B
BetaN/A
PE Ratio (TTM)20.06
EPS (TTM)237.00
Earnings DateMay 18, 2018
Forward Dividend & Yield2.53 (4.37%)
Ex-Dividend Date2017-08-10
1y Target Est75.03
  • Financial Times14 minutes ago

    [$$] AstraZeneca hails ‘milestone’ US approval for lung cancer drug

    AstraZeneca’s R&D-led turnround strategy received an important boost on Monday after US authorities approved the use of one of its key new lung cancer drugs, reinforcing the medicine’s potential to become ...

  • Reuters4 hours ago

    AstraZeneca's immunotherapy drug wins key lung cancer approval

    AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors. The U.S. Food and Drug Administration (FDA) said late on Friday it had granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients with inoperable mid-stage disease that has not spread widely around the body. Imfinzi is the first immunotherapy to be approved in this setting and the company's shares rose 1 percent in early trade on Monday.

  • Financial Times5 hours ago

    [$$] AstraZeneca wins FDA approval for key cancer drug

    AstraZeneca’s turnround efforts received a boost on Monday as US authorities approved the use of one of its key new lung cancer drugs. The Food and Drug Administration has approved Imfinzi for treating ...

  • Reuters2 days ago

    AstraZeneca's immunotherapy drug wins key lung cancer approval

    AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors. The U.S. Food and Drug Administration said late on Friday it granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients with inoperable mid-stage disease that has not spread widely around the body.

  • Reuters3 days ago

    U.S. FDA approves AstraZeneca's immunotherapy for lung cancer

    Lung cancer is the leading cause of cancer death in the United States, with an estimated 222,500 new diagnoses and 155,870 deaths in 2017, according to the National Cancer Institute. In 2017, the drug was approved to treat a type of bladder cancer in patients whose disease progressed despite chemotherapy.

  • Reuters3 days ago

    U.S. FDA approves AstraZeneca's immunotherapy for lung cancer

    The U.S. Food and Drug Administration on Friday granted approval for expanded use of AstraZeneca Plc's , immunotherapy drug, Imfinzi, to treat non-small cell lung cancer whose tumors can't be surgically removed. Imfinzi, chemically known as durvalumab, belongs to a new class of oncology drugs called PD-L1 inhibitors that block a mechanism tumors use to evade detection from the immune system. Lung cancer is the leading cause of cancer death in the United States, with an estimated 222,500 new diagnoses and 155,870 deaths in 2017, according to the National Cancer Institute.

  • Cyclicals, South Africa-exposed stocks help steady FTSE 100
    Reuters4 days ago

    Cyclicals, South Africa-exposed stocks help steady FTSE 100

    By Kit Rees LONDON (Reuters) - A rally in miners and stocks exposed to South Africa helped Britain's top share index close higher for a second day in a row on Thursday, stabilising after last week's hefty ...

  • Financial Times4 days ago

    [$$] Irish drugmaker Horizon Pharma raises painkiller price to $3,000 in US

    An Irish drugmaker has put a price tag of almost $3,000 on a bottle of two-in-one painkillers that can be bought separately for $36, in another instance of gouging in the US, the world’s largest healthcare ...

  • Commodities help FTSE 100 outperform European stocks
    Reuters6 days ago

    Commodities help FTSE 100 outperform European stocks

    By Kit Rees and Helen Reid LONDON (Reuters) - A recovery among commodities stocks helped Britain's top share index outperform European peers on Tuesday, though it came under pressure from a firmer pound ...

  • Reuters11 days ago

    FTSE slides after BOE meeting as pound pops higher

    By Danilo Masoni and Kit Rees MILAN/LONDON (Reuters) - The UK's top share index fell on Thursday after the Bank of England raised the prospect of higher interest rates, sending the pound higher which weighed ...

  • Benzinga11 days ago

    The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease

    "Age is just a number, not a state of mind or a reason for any type of particular behavior." -Cecelia Ahern Alzheimer's disease is the sixth leading cause of death in the U.S., although recent ...

  • Reuters12 days ago

    GlaxoSmithKline sees light at end of Advair tunnel

    GlaxoSmithKline (GSK.L) sees growth strengthening over the next few years as the drugmaker weathers increased competition in its core respiratory and HIV businesses that could cause earnings to dip this year. Despite this threat and looming competition from a new Gilead Sciences (GILD.O) HIV drug, Chief Executive Emma Walmsley is more optimistic GSK will deliver on a promise of mid to high single digit earnings growth in the five years to 2020. Walmsley, who took over 10 months ago, is battling to rebuild GSK's drug pipeline by refocusing its research and appointing heavyweight outsiders, such as veteran Roche (ROG.S) scientist Hal Barron.

  • MarketWatch13 days ago

    Bristol-Myers touts lung cancer breakthrough, but critics cry foul

    The drugmaker says its findings advanced the scientific understanding of how to treat lung cancer, but critics say a major overhaul of the clinical trial design sullied the results.

  • BNP Paribas says it posted a 'solid' 2017 despite profit slump in last quarter
    CNBC13 days ago

    BNP Paribas says it posted a 'solid' 2017 despite profit slump in last quarter

    French lender BNP Paribas reported a worse than expected net profit for its fourth quarter of 2017, falling 1.1 percent to 1.43 billion euros ($1.77 billion) and missing market expectations.

  • Foreign Stock Roundup: RDS.A & AZN Impress, NVO & BABA Disappoint
    Zacks14 days ago

    Foreign Stock Roundup: RDS.A & AZN Impress, NVO & BABA Disappoint

    Losses on Wall Street and falling bond yields weighed on global markets this week.

  • Is AstraZeneca PLC (LON:AZN) An Attractive Dividend Stock?
    Simply Wall St.16 days ago

    Is AstraZeneca PLC (LON:AZN) An Attractive Dividend Stock?

    Dividends play a key role in compounding returns over time and can form a large part of our portfolio return. Over the past 10 years, AstraZeneca PLC (LSE:AZN) has returnedRead More...

  • AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro
    Investor's Business Daily17 days ago

    AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro

    AstraZeneca's Lynparza is now king of the U.S. PARP inhibitor realm — beating out Tesaro — an analyst said Friday.

  • MarketWatch17 days ago

    FTSE 100 suffers worst week since April as bond yields spike

    U.K.’s benchmark stock index dropped for a fourth straight day on Friday, extending its weekly loss, after bond yields spiked following a better-than-expected reading on the U.S. labor market.

  • Reuters17 days ago

    Results, risk aversion drag FTSE 100 to worst week in nine months

    By Kit Rees LONDON (Reuters) - Britain's top share index sealed its worst week in nine months on Friday after results from BT were met with disappointment and commodities stocks tumbled amid a global equity ...

  • Reuters17 days ago

    AstraZeneca flags return to drug growth in 2018, China shines

    AstraZeneca (AZN.L) expects a return to drug sales growth in 2018 as new medicines win market share and the group puts patent losses behind it, although the need to invest in launches will weigh on profit this year. AstraZeneca has suffered the industry's biggest patent cliff since 2012, wiping out more than half of its sales, but Chief Executive Pascal Soriot said it was turning a corner and spending as a proportion of sales would reduce by 2019-20. After a 5 percent fall in 2017, the group expects drug sales this year to grow at a low single-figure percentage rate, driven by new treatments for cancer, in particular, and buoyed by 20 percent-plus sales growth in China.

  • AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018
    Zacks17 days ago

    AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018

    AstraZeneca (AZN) beats earnings estimates in fourth quarter on higher product revenues.

  • Reuters17 days ago

    AstraZeneca links with Alibaba and Tencent in China push

    AstraZeneca (AZN.L) has clinched two new deals with Chinese tech giants Alibaba (BABA.N) and Tencent as the British drugmaker steps up its drive to expand business in China. China is now the world's second-largest drugs market behind the United States and is a particular bright spot for AstraZeneca, accounting for 15 percent of its drug sales -- a far higher proportion than at other big pharmaceutical companies. AstraZeneca's sales in China grew 30 percent in the last quarter of 2017 and Chief Executive Pascal Soriot expects them to continue to increase at a "low-20s" percentage rate.

  • Reuters17 days ago

    AstraZeneca links with Alibaba and Tencent in China push

    AstraZeneca has clinched two new deals with Chinese tech giants Alibaba and Tencent as the British drugmaker steps up its drive to expand business in China. China is now the world's second-largest drugs market behind the United States and is a particular bright spot for AstraZeneca, accounting for 15 percent of its drug sales -- a far higher proportion than at other big pharmaceutical companies. AstraZeneca's sales in China grew 30 percent in the last quarter of 2017 and Chief Executive Pascal Soriot expects them to continue to increase at a "low-20s" percentage rate.

  • Associated Press17 days ago

    Astrazeneca beats 4Q profit forecasts

    The Cambridge, Britain-based company said it had net income of $1.03 per share. Earnings, adjusted for non-recurring costs, were $1.30 per share. The results exceeded Wall Street expectations. The average ...

  • Reuters17 days ago

    Deutsche Bank drags European shares towards worst weekly loss since August

    European shares were set for their biggest weekly loss in six months on Friday as a slump in Deutsche Bank (DBKGn.DE) on a disappointing update dragged the heavyweight banking sector lower after a strong start to the year. "The stock market cannot always go up and multiples are very high. Vailati said European shares were more vulnerable than their U.S. peers to possible pull back because earnings growth expectations were stable, whereas those for U.S. companies were being revised upwards thanks to measures there to cut taxes.